A Phase I Open-label, Non-randomized, Dose-escalation First-in-man Trial to Investigate the c-Met Kinase Inhibitor EMD 1204831 in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2012
At a glance
- Drugs EMD 1204831 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 27 Jun 2012 Actual patients number is 38 as reported by ClinicalTrials.gov.
- 27 Jun 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 27 Jun 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.